Both IDFS and OS with paclitaxel were clearly better in the obese group (with a strong trend in the severely obese group, as well as BCOS in heavier people) while no significant differences were seen in the normal BMI group irrespective of inclusion of paclitaxel or not.
← all excerpts
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.
1
—
—